Low-dose IL-2 mitigates glucocorticoid-induced Treg impairment and promotes improvement of SLE

Signal Transduct Target Ther. 2023 Apr 3;8(1):141. doi: 10.1038/s41392-023-01350-6.
No abstract available

Publication types

  • Letter
  • Research Support, Non-U.S. Gov't

MeSH terms

  • CD4-Positive T-Lymphocytes
  • Glucocorticoids / pharmacology
  • Humans
  • Interleukin-2 / genetics
  • Lupus Erythematosus, Systemic* / drug therapy
  • Lupus Erythematosus, Systemic* / genetics
  • T-Lymphocytes, Regulatory*

Substances

  • Glucocorticoids
  • Interleukin-2